Develops, manufactures and sells generic, branded and rare-disease pharmaceutical products to wholesalers, pharmacies and healthcare providers.
10-K for FY2025, filed Feb 27, 2026
ANI earns revenue mainly from sales of generic, rare-disease and branded medicines, plus royalties and pharmaceutical services. Product sales are counted when products transfer to customers; customers generally pay within 100 days.
10-K for FY2025, filed Feb 27, 2026Revenues are primarily derived from sales of generic, rare disease, and brands portfolio pharmaceutical products, royalties, and other…View ↗
Years Ended December 31, Products and Services (in thousands) 2025 2024 2023 Rare Disease and Brands Cortrophin Gel $ 347,778 $ 198,085 $…View ↗
Years Ended December 31, Timing of Revenue Recognition (in thousands) 2025 2024 2023 Performance obligations transferred at a point in time…View ↗
10-K for FY2025, filed Feb 27, 2026
FY2025 revenue by reportable segment ↗$883.4M
10-K for FY2025, filed Feb 27, 2026
$883.4M ↗| Segment | Share | Revenue | How money arrives |
|---|---|---|---|
|
Generics and Other
|
45%
FY2022: 74%
|
Generics and Other, FY2025
$399.4M Sources
|
|
|
Rare Disease and Brands
Sold outright
10-K for FY2025, filed Feb 27, 2026 |
55%
FY2022: 26%
|
Rare Disease and Brands, FY2025
$483.9M Sources
|
Sold outright |
Wholesalers, pharmacies and distributors move ANI's medicines to patients. Cortrophin Gel goes through a limited specialty-pharmacy network; ANI also contracts with certain hospital systems, clinics and physicians for ILUVIEN.
10-K for FY2025, filed Feb 27, 2026Our customers include national wholesalers, specialty pharmacies, retail pharmacy chains, distributors, mail order houses, group purchasing…View ↗
In the Rare Disease business, specifically for Cortrophin Gel, there is a limited distribution network and a select group of specialty…View ↗
We market, sell, and distribute our products in the U.S. and internationally. Our products are distributed through the following channels:View ↗
Yes. It kept 9 cents of every revenue dollar as net income in FY2025 and turned 19 cents into free cash flow.
10-Q for Q3 FY2026, filed Nov 5, 2026
Open tableView ↗
8-K, filed Nov 5, 2026
The completion of the Offer is subject to certain customary closing conditions for an offer governed by the Swedish Takeover Rules…View ↗
8-K, filed Apr 7, 2026
On April 1, 2026, ANI Pharmaceuticals, Inc. (the “Company”) notified EisnerAmper LLP (“EisnerAmper”) that EisnerAmper would be dismissed as…View ↗
Growing. Revenue grew 4.1x in 4 years, from $216.1M in FY2021 to $883.4M in FY2025, about 42% a year.
Rare Disease expands
ANI's Rare Disease offering shifts from a platform centered on Cortrophin Gel to one that also includes ILUVIEN and YUTIQ after acquiring Alimera.
10-K for FY2022, filed Mar 9, 2023 10-K for FY2025, filed Feb 27, 2026During 2021 and 2022, we invested in leadership, expertise and infrastructure in the areas of commercialization of rare disease therapies…View ↗
In September 2024, we acquired ILUVIEN and YUTIQ (together, the "Retina Franchise") in connection with the acquisition of Alimera. The…View ↗
Loading...